Oxford AstraZeneca vaccination rollout and safety update

The European nations which paused their Oxford AstraZeneca vaccinations due to safety concerns have announced they will resume. This followed after the European Medicines Agency advised the vaccine was not linked to an overall increased risk of blood clots. You can read more here.

In further reassuring news today, the Therapeutic Goods Administration in Australia reported that an independent expert review of the Oxford AstraZeneca vaccine concluded there is no increased risk of anaphylaxis associated with the vaccine above the expected rate for any other vaccine. You can find out more about the review here.

You can stay informed of latest developments on the Monash Health employee vaccination hub here.


Approved by David Bloxham, Director Public Affairs and Communication



Previous Next
Test Caption
Test Description goes like this
This website is for Monash Health employees. Please be mindful before sharing links.Learn more